secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2023-12-05T23:59:59+00:00
Accession:  0001104659-23-123459
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune CERPASS trial misses primary endpoints; BLA for RP1 in melanoma planned 2H 2024
--------------------------------------------------------------------------------

- CERPASS trial of RP1+cemiplimab in CSCC did not meet primary endpoints; CRR 38.1% vs 25% (p=0.040 just below threshold).
- In anti-PD1 failed melanoma (IGNYTE, n=156), ORR 31.4% (12% CR); median DOR >24 months; BLA submission planned for 2H 2024.
- RP1 monotherapy (ARTACUS) in transplant patients: 34.8% ORR, 5 CRs, no allograft rejection.
- Portfolio reprioritization: discontinue RP2/3 in SCCHN/CRC and RP3 development; focus on RP1 melanoma and RP2 uveal melanoma.
- Cash $496.8M as of Sept 30, 2023; cash runway extended into early 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465923123459/0001104659-23-123459-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465923123459/tm2332152d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-123459

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer